In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Therapeutics

Executive Summary

Cardiovascular drug discovery firm completes $16.6 mil. mezzanine round of financing through private placement of preferred stock. The Mountain View, Calif.-based company initiated its first clinical trial in February for CVT-1, an orally active cholesterol-lowering product designed to inhibit a "cholesterol transport protein that plays a key role in promoting the absorption of cholesterol from the intestine," the firm said. CVT was founded in 1992 and previously raised $13 mil. in two rounds of venture financing



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts